Megan Price, MSN, APRN, FNP-C, Virginia Seery, CRNP, MSN, Laura Wood, RN, MSN, OCN
Combination therapy continues to evolve in the renal-cell carcinoma space. However, along with improved efficacy come the tests of adverse events and their impact on quality of life. Please join Laura Wood, RN, MSN, OCN, Virginia Seery, MSN, RN, ANP-BC, AOCNP, and Megan Price, MSN, APRN, FNP-C, as they discuss the ways in which drug combinations improve outcomes but also present their own set of challenges for patients’ quality of life.
Please submit your manuscripts using the form below. Papers submitted to our journal usually have a first decision within 4-6 weeks. If you have any questions, please contact the Editorial Director at firstname.lastname@example.org.